Welcome to our dedicated page for Monopar Therapeutics SEC filings (Ticker: MNPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Monopar Therapeutics Inc. filings document a clinical-stage biopharmaceutical issuer focused on ALXN1840 for Wilson disease and MNPR-101 radiopharmaceutical programs for uPAR-expressing cancers. Its 8-K reports furnish financial results, business updates, Regulation FD clinical presentations, conference materials and executive leadership changes, including ALXN1840 Phase 2 and Phase 3 analyses and MNPR-101 program regulatory updates.
Proxy and material-event filings cover shareholder voting matters, board governance, executive compensation, pay-versus-performance tables, capital-structure disclosures and material agreements. The filing record also provides formal context for reported operating results, financing activity and disclosures tied to investigational drug development and Nasdaq-listed common stock.
Monopar Therapeutics Inc. filed a current report to share that it presented clinical trial results at a major medical conference. On May 29, 2026, the company presented results from a Phase 2 study (NCT04422431) of ALXN1840 (tiomolibdate choline) in patients with Wilson disease at the European Association for the Study of the Liver International Liver Congress 2026.
The related scientific presentation is furnished as Exhibit 99.1 and is incorporated by reference, providing more detailed information on the Phase 2 study’s evaluation of liver pathology and clinical symptoms in Wilson disease.
Monopar Therapeutics Inc. reported that a peer-reviewed manuscript in Hepatology Communications has published Phase 2 ALXN1840-WD-204 trial results for ALXN1840 (tiomolibdate choline) in Wilson disease. The open-label study in nine patients showed rapid, statistically significant and sustained improvement in daily copper balance, mainly through increased fecal copper excretion.
The publication notes patients had a mean 16 years of prior standard-of-care treatment yet still had substantial residual copper that ALXN1840 mobilized and eliminated. Monopar also references a completed 48-week Phase 3 trial in 266 patients over 645 patient-years, where ALXN1840 demonstrated greater copper mobilization than standard care and a favorable safety profile, while cautioning that future outcomes depend on regulatory processes, market acceptance and funding.
Monopar Therapeutics Inc. ownership disclosure: Saturn V Capital Management LP and Xiaoying Tian report a shared beneficial interest of 345,626 shares of Common Stock, representing 5.20% of the class. The filing cites 6,698,778 shares outstanding as of April 27, 2026.
The report states Saturn V acts as investment manager for pooled vehicles and managed accounts that hold the shares and that both reporting persons disclaim direct beneficial ownership while retaining voting and dispositive power on behalf of those Clients.
Monopar Therapeutics reported a net loss of $3.9M for the quarter ended March 31, 2026, wider than the $2.6M loss a year earlier, as it increased spending on its drug pipeline. Research and development expenses rose to $3.5M from $1.6M, while general and administrative costs were $1.7M.
The company had $137.5M in cash, cash equivalents and investments as of March 31, 2026, and management believes this will fund operations at least through December 31, 2027. Monopar remains a clinical-stage biopharmaceutical company with no product revenue, focused on ALXN1840 for Wilson disease and radiopharmaceutical programs for advanced cancers.
Monopar Therapeutics reported first quarter 2026 results and highlighted progress on its ALXN1840 program for Wilson disease. The company remains on track to submit a New Drug Application to the U.S. Food and Drug Administration in mid-2026 and is preparing for a potential launch, led by its Chief Commercial and Strategy Officer.
Cash, cash equivalents and investments were $137.5 million as of March 31, 2026, and Monopar expects this to fund operations at least through December 31, 2027, including regulatory and potential commercial activities for ALXN1840 and continued development of MNPR-101 programs. Net loss for the quarter was $3.9 million, or $0.46 per share, compared with $2.6 million, or $0.38 per share, a year earlier.
Research and development expenses rose to $3,487,247 from $1,643,375, mainly due to higher contractor, consulting, and personnel costs, while general and administrative expenses increased to $1,738,006 from $1,578,442. Interest income increased to $1,332,203 from $596,845, driven by earnings on U.S. Treasury securities, commercial paper, and higher bank balances following approximately $91.9 million of net proceeds from a September 2025 capital raise.
Monopar Therapeutics Schedule 13G/A: Adage Capital Management, L.P. and affiliated reporting persons report beneficial ownership of 424,195 shares of Common Stock, representing 6.23% of the class, calculated on 6,692,140 shares outstanding as of March 17, 2026. The reported holdings include 115,000 shares issuable upon exercise of warrants held by Adage Capital Partners, L.P.
The filing attributes shared voting and dispositive power over the reported shares to the reporting persons and states their business address in Boston, Massachusetts.
Monopar Therapeutics Inc. is asking stockholders at its June 22, 2026 annual meeting to elect six directors, including new nominee Nicole Sweeny, approve executive pay on an advisory basis, adopt a new 2026 Stock Incentive Plan, and ratify BPM LLP as auditor.
Stockholders of record as of April 27, 2026, when 6,698,778 common shares were outstanding, may vote. The 2026 plan would add 600,000 new shares plus remaining and recycled shares from the prior plan, with new award capacity equal to 9.2% of fully diluted common stock as of March 31, 2026. The proxy also details director fees, substantial 2025 equity and cash compensation for executives, change-in-control severance protections, and pay-versus-performance disclosures comparing compensation actually paid to total shareholder return and net losses.
Monopar Therapeutics Inc. is highlighting new Phase 3 data for ALXN1840 (tiomolibdate choline) in Wilson disease. Analyses from the randomized controlled FoCus trial showed greater neurologic improvement and significantly less worsening versus standard of care through Week 48 in patients with neurologic symptoms at baseline, with durable benefit over multiple years of treatment. These results, presented at the American Academy of Neurology 2026 meeting in a late-breaker oral and poster session, support Monopar’s plan to advance ALXN1840 toward a New Drug Application submission to the U.S. Food and Drug Administration in mid-2026.
Monopar Therapeutics Chief Executive Officer Chandler Robinson reported routine equity compensation activity. On March 31, 2026, 6,732 restricted stock units vested and were settled into an equal number of common shares at an exercise price of $0.00 per share.
Of these shares, 1,972 were withheld by the issuer at $54.79 per share to cover applicable tax withholding obligations. Following these transactions, Robinson held 90,478 shares of common stock directly and 62,815 shares indirectly through the Chandler D. Robinson Irrevocable Trust U/A dated May 20, 2020.